Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp433 | Osteoporosis: treatment | ECTS2013

Denosumab is associated with progressive improvements in hip cortical mass and thickness

Poole K , Treece G , Gee A , Brown J P , McClung M R , Wang A , Libanati C

Denosumab (DMAb) significantly improves bone strength at the hip, estimated by FEA from QCT scans, from baseline (B/L) and vs placebo (Pbo) (Keaveny ASBMR 2010). We determined the extent and distribution of mass and thickness changes at the proximal femur, a key skeletal site for fracture risk, using a novel cortical bone mapping technique on the same serial QCT scans. A FREEDOM substudy included 80 women who underwent hip QCT scanning at B/L and months 12, 24 and 36 during DM...